

ANTIBIOTICS: TECHNOLOGIES AND GLOBAL MARKETS



PHM025C
May 2014

Neha Maliwal
Project Analyst

ISBN: 1-56965-812-9

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	3
INTENDED AUDIENCE	3
RESEARCH METHODOLOGY	3
ANALYST CREDENTIALS	5
RELATED BCC RESEARCH REPORTS	5
BCC RESEARCH WEBSITE	5
DISCLAIMER	5
CHAPTER 2 EXECUTIVE SUMMARY	7
<i>SUMMARY TABLE GLOBAL ANTIBIOTICS MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE GLOBAL ANTIBIOTICS MARKET BY REGION, 2013-2018 (\$ MILLIONS)</i>	8
CHAPTER 3 MARKET OVERVIEW	10
INTRODUCTION	10
BACTERIA	10
<i>TABLE 1 DIFFERENCES BETWEEN GRAM-NEGATIVE AND GRAM-POSITIVE BACTERIA</i>	11
GRAM-POSITIVE BACTERIA	11
GRAM-NEGATIVE BACTERIA	12
Mycobacterium	12
<i>TABLE 2 CLASSIFICATION OF BACTERIA BY SHAPE</i>	13
BACTERIAL INFECTIONS	14
RESPIRATORY TRACT INFECTIONS	14
<i>TABLE 3 INCIDENCE OF COMMUNITY-ACQUIRED PNEUMONIA, 2010 (NO./%)</i>	15
<i>TABLE 4 INCIDENCE OF UPPER RESPIRATORY TRACT INFECTIONS CAUSED BY STREPTOCOCCUS, 2010 (NO./%)</i>	15
URINARY TRACT INFECTIONS	15
<i>TABLE 5 INCIDENCE OF URINARY TRACT INFECTIONS CAUSED BY STREPTOCOCCUS, 2010 (NO./%)</i>	16
SKIN AND SKIN STRUCTURE INFECTIONS	16
<i>TABLE 6 INCIDENCE OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY STREPTOCOCCUS, 2010 (NO./%)</i>	16
Cellulitis and Erysipelas	17
Folliculitis	17
Impetigo and Ecthyma	17
Abscesses	17
Carbuncles and Furuncles	17
GYNECOLOGICAL INFECTIONS	17
<i>TABLE 7 PREVALENCE OF BACTERIAL VAGINOSIS INFECTIONS CAUSED BY STREPTOCOCCUS, 2010 (NO./%)</i>	17
ANTIBIOTIC-RESISTANT BACTERIA	18
<i>TABLE 8 TYPES OF ANTIBIOTICS AND METHODS OF RESISTANCE</i>	18
<i>TABLE 9 CURRENT AND EMERGING ANTIBIOTIC-RESISTANT BACTERIA</i>	19

TOPIC	PAGE NO.
DEFINITION OF ANTIBIOTIC	21
CLASSIFICATION OF ANTIBIOTICS	21
<i>FIGURE 1 CLASSIFICATION OF ANTIBIOTICS</i>	21
HISTORY OF ANTIBIOTICS AND CURRENT STATUS	22
PRE-ANTIBIOTIC ERA	22
ANTIBIOTIC ERA	22
<i>TABLE 10 U.S. LIFE EXPECTANCY AT BIRTH, 1920-2011 (YEARS)</i>	23
<i>TABLE 11 ANTIBIOTICS: YEAR OF INTRODUCTION, MODE OF ACTION AND TARGET SPECIES</i>	23
EMERGENCE OF POST-ANTIBIOTIC ERA	24
<i>TABLE 12 BIOCHEMICAL MECHANISM OF ANTIBIOTIC RESISTANCE</i>	25
<i>FIGURE 2 CDC LIST OF MOST HIGHLY CONCERNING BACTERIA, PRIORITIZED ACCORDING TO THREAT LEVEL</i>	26
<i>TABLE 13 ADDITIONAL COST AND LENGTH OF STAY DUE TO ANTIBIOTIC-RESISTANT BACTERIA IN THE U.S., ISRAEL AND SPAIN</i>	26
DRIVERS RESTRAINTS AND OPPORTUNITIES	27
DRIVERS	27
Growth of the Global Pharmaceutical Market Driven by Antibiotics	27
Aging Population Propels the Growth of the Antibiotics Market	28
<i>FIGURE 3 INCREASE IN AGING POPULATION, 2011 AND 2050 (BILLIONS)</i>	28
Public-Private Partnerships Encourage Antibiotic Development	29
Increasing Prevalence of Hospital-Acquired Infections Triggers Market Growth	29
RESTRAINTS	30
Antibiotic Resistance	30
Declining R&D Investment Poses Long-Term Barrier to Market Growth	31
Genericization of Antibiotics Restrains Market Growth	31
OPPORTUNITIES	32
Market Expansion into Emerging Countries	32
Multidrug-Resistant Pathogens Provide an Opportunity to Develop Novel Antibacterial Agents	32
MARKET SHARES OF KEY COMPANIES	33
<i>FIGURE 4 GLOBAL ANTIBIOTIC COMPANY MARKET SHARES, 2012 (%)</i>	33
REGULATORY ISSUES	35
FDA AND INTERNATIONAL REGULATORY AGENCIES	35
RECENT REGULATORY REFORMS	36
KETEK CASE STUDY	36
KEY TRENDS AFFECTING THE MARKET	37
NEVER EVENTS	37
Impact on the Use of Antibiotics	38
FUNDING FOR NEW ANTIBIOTICS	38
United States	38
Infectious Diseases Society of America	38
NIH Funding	39
Public-Private Partnerships	39
Europe	40
Innovative Medicines Initiative	40
EMERGING DRUGS WITH NOVEL MECHANISMS OF ACTION	41

TOPIC	PAGE NO.
PharmaSea Project	41
Combination of Different Antibiotics	41
Others	42
CHAPTER 4 ANTIBIOTIC RESEARCH AND DEVELOPMENT	44
REASONS FOR LACK OF INNOVATION IN ANTIBIOTIC RESEARCH	44
<i>TABLE 14 REASONS FOR LACK OF INNOVATION IN ANTIBIOTIC RESEARCH</i>	<i>45</i>
LOW RETURN ON INVESTMENT	45
STRICT REGULATORY ENVIRONMENT	46
SCIENTIFIC CHALLENGES	47
STRATEGIES TO PROMOTE ANTIBIOTIC RESEARCH	47
<i>FIGURE 5 STRATEGIES TO PROMOTE ANTIBIOTIC RESEARCH</i>	<i>48</i>
PUSH STRATEGIES	48
Increasing Access to Research	48
Increasing the Number of Scientific Personnel	49
Direct Funding of Research	50
Translational Research	51
Tax Incentives	52
Product Development Partnerships	52
PULL STRATEGIES	52
Monetary Awards	53
Advance Market Commitments	53
Legal and Regulatory Initiatives	54
Clinical Trials	54
Accelerated Regulatory Review	55
Intellectual Property Rights Strategies	55
Increasing the Term of IP Protection and Data Exclusivity	56
Wildcard Patent Extension	57
Patent Buyouts	57
Pricing and Reimbursement	57
Other Legal/Regulatory Strategies	58
COMBINED PULL AND PUSH INCENTIVES	58
ORPHAN DRUG STATUS	58
<i>TABLE 15 COMPARISON OF U.S. AND EU ORPHAN DRUG LEGISLATION AND PROCESS</i>	<i>59</i>
CHAPTER 5 ANTIBIOTICS MARKET BY TYPE	61
MARKET SIZE ESTIMATION	61
MARKET SHARE ESTIMATION	61
GLOBAL ANTIBIOTICS MARKET BY CLASS	62
<i>TABLE 16 GLOBAL ANTIBIOTICS MARKET BY CLASS, THROUGH 2018 (\$ MILLIONS)</i>	<i>62</i>
<i>TABLE 17 GLOBAL ANTIBIOTICS MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	<i>62</i>
<i>FIGURE 6 ANTIBIOTICS BY CLASS</i>	<i>62</i>
BETA-LACTAM ANTIBIOTICS	63
<i>TABLE 18 GLOBAL BETA-LACTAM ANTIBIOTICS MARKET BY TYPE, THROUGH 2018 (\$ MILLIONS)</i>	<i>63</i>
<i>TABLE 19 GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	<i>64</i>

TOPIC	PAGE NO.
Extended Spectrum Beta-Lactamase	64
Metallo-Beta-Lactamases	65
<i>FIGURE 7 TYPES OF BETA-LACTAM ANTIBIOTICS</i>	65
Penicillins	65
<i>TABLE 20 GLOBAL PENICILLIN MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	66
<i>TABLE 21 TYPES OF PENICILLIN AND BRAND NAMES</i>	67
Cephalosporins	67
Side Effects	68
<i>TABLE 22 GLOBAL CEPHALOSPORIN MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	68
Teflaro Driving the Cephalosporin Market	69
Generations of Cephalosporins	69
<i>TABLE 23 GENERATIONS OF CEPHALOSPORIN</i>	69
First-Generation Cephalosporins	69
<i>TABLE 24 FIRST-GENERATION CEPHALOSPORINS</i>	70
Second-Generation Cephalosporins	70
<i>TABLE 25 SECOND-GENERATION CEPHALOSPORINS</i>	71
Third-Generation Cephalosporins	71
Antipseudomonal Cephalosporins	72
<i>TABLE 26 THIRD-GENERATION CEPHALOSPORINS</i>	72
Fourth-Generation Cephalosporins	72
<i>TABLE 27 FOURTH-GENERATION CEPHALOSPORINS</i>	73
Fifth-Generation Cephalosporins	73
<i>TABLE 28 FIFTH-GENERATION CEPHALOSPORINS</i>	73
Carbapenems	74
<i>TABLE 29 GLOBAL CARBAPENEM MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	74
<i>TABLE 30 TYPES OF CARBAPENEMS</i>	75
QUINOLONES AND FLUOROQUINOLONES	75
<i>TABLE 31 GLOBAL MARKET FOR QUINOLONES BY GENERATION, THROUGH 2018 (\$ MILLIONS)</i>	76
<i>TABLE 32 GLOBAL MARKET FOR FLUOROQUINOLONES BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	77
Generations of Quinolones	77
First-Generation Quinolones	77
Second-Generation Fluoroquinolones	77
<i>TABLE 33 GLOBAL MARKET FOR SECOND-GENERATION FLUOROQUINOLONES BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	78
Third-Generation Fluoroquinolones	79
<i>TABLE 34 GLOBAL MARKET FOR THIRD-GENERATION FLUOROQUINOLONES BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	79
Levofloxacin: A Major Driver of the Market for Third-Generation Fluoroquinolones	79
Fourth-Generation Fluoroquinolones	80
<i>TABLE 35 GLOBAL MARKET FOR "OTHER" QUINOLONES BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	80
<i>TABLE 36 TYPES OF QUINOLONES</i>	80
TETRACYCLINE	81
<i>TABLE 37 GLOBAL TETRACYCLINE MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	82

TOPIC	PAGE NO.
<i>TABLE 38 TYPES OF TETRACYCLINE</i>	82
MACROLIDES	83
<i>TABLE 39 GLOBAL MACROLIDE MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	84
Ketolides	84
Ketek	84
<i>TABLE 40 TYPES OF MACROLIDES/KETOLIDES</i>	84
OTHER ANTIBIOTICS	85
<i>TABLE 41 GLOBAL MARKET FOR "OTHER" ANTIBIOTICS BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	85
CHAPTER 6 VETERINARY ANTIBIOTICS MARKET	87
INTRODUCTION	87
<i>TABLE 42 DIFFERENCES BETWEEN ANTIBIOTIC USAGE IN ANIMALS AND HUMANS</i>	87
<i>TABLE 43 GLOBAL MARKET FOR VETERINARY ANTIBIOTICS BY APPLICATION, THROUGH 2018 (\$ MILLIONS)</i>	88
VETERINARY APPLICATIONS	88
FEED APPLICATION	88
FDA to Phase out Antibiotics from Food Production	89
THERAPEUTIC APPLICATIONS	89
<i>TABLE 44 GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY TYPE, THROUGH 2018 (\$ MILLIONS)</i>	90
<i>TABLE 45 GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY ANIMAL TYPE, THROUGH 2018 (\$ MILLIONS)</i>	90
OTHER APPLICATIONS	91
CHAPTER 7 COMPANY PROFILES	94
ASTRAZENECA	94
FINANCIALS	94
<i>TABLE 46 ASTRAZENECA REVENUES AND R&D EXPENDITURES, 2011-2013 (\$ MILLIONS)</i>	94
DEVELOPMENTS	95
<i>TABLE 47 ASTRAZENECA DEVELOPMENTS</i>	95
BAYER HEALTHCARE AG	95
FINANCIALS	96
<i>TABLE 48 BAYER REVENUES AND R & D EXPENDITURES, 2011-2013 (\$ MILLIONS)</i>	96
DEVELOPMENTS	96
CUBIST PHARMACEUTICALS	96
FINANCIALS	96
<i>TABLE 49 CUBIST PHARMACEUTICAL REVENUES AND R&D EXPENDITURES, 2011-2013</i>	97
DEVELOPMENTS	97
<i>TABLE 50 CUBIST PHARMACEUTICAL DEVELOPMENTS</i>	97
GLAXOSMITHKLINE	98
FINANCIALS	99
<i>TABLE 51 GSK REVENUES AND R & D EXPENDITURES, 2011-2013 (\$ MILLIONS)</i>	99
DEVELOPMENTS	99
<i>TABLE 52 GSK DEVELOPMENTS</i>	99
JOHNSON & JOHNSON	100
FINANCIALS	100

TOPIC	PAGE NO.
<i>TABLE 53 JOHNSON & JOHNSON REVENUES AND R&D EXPENDITURES, 2011-2013 (\$ MILLIONS)</i>	100
DEVELOPMENTS	101
<i>TABLE 54 JOHNSON & JOHNSON DEVELOPMENTS</i>	101
MERCK & CO.	101
FINANCIALS	102
<i>TABLE 55 MERCK & CO. REVENUES AND R&D EXPENDITURES, 2011-2013 (\$ MILLIONS)</i>	102
DEVELOPMENTS	102
PFIZER	102
FINANCIALS	103
<i>TABLE 56 PFIZER REVENUES AND R&D EXPENDITURES, 2011-2013 (\$ MILLIONS)</i>	103
DEVELOPMENTS	103
<i>TABLE 57 PFIZER DEVELOPMENTS</i>	103
<i>TABLE 58 LIST OF OTHER COMPANIES IN THE ANTIBIOTICS MARKET</i>	104
CHAPTER 8 CLINICAL TRIALS ON ANTIBIOTICS	108
<i>FIGURE 8 ANTIBIOTICS IN PHASES I-III CLINICAL TRIALS, 2013 (%)</i>	109
ANTIBIOTICS IN PHASE III CLINICAL TRIALS	110
<i>FIGURE 9 ANTIBIOTICS IN PHASE III CLINICAL TRIALS BY CLASS, 2013 (%)</i>	110
<i>TABLE 59 ANTIBIOTIC COMPOUNDS IN PHASE III CLINICAL TRIALS, 2013</i>	111
ANTIBIOTICS IN PHASE II CLINICAL TRIALS	112
<i>TABLE 60 ANTIBIOTIC COMPOUNDS IN PHASE II CLINICAL TRIALS, 2013</i>	112
ANTIBIOTICS IN PHASE I CLINICAL TRIALS	113
<i>TABLE 61 ANTIBIOTIC COMPOUNDS IN PHASE I CLINICAL TRIALS, 2013</i>	113
CHAPTER 9 APPENDIX A: OVERVIEW OF BACTERIA TYPES	116
DISEASE ORGANISMS, DIAGNOSTICS, CLINICAL MANIFESTATIONS AND TREATMENTS	116
<i>TABLE 62 GRAM-POSITIVE BACTERIA</i>	116
<i>TABLE 63 GRAM-NEGATIVE BACTERIA</i>	119
<i>TABLE 64 GRAM-NEGATIVE COCCI</i>	125
<i>TABLE 65 GRAM-NEGATIVE RODS RELATED TO RESPIRATORY TRACT INFECTIONS</i>	127
<i>TABLE 66 GRAM-NEGATIVE RODS RELATED TO THE ENTERIC TRACT</i>	128
<i>TABLE 67 GRAM-NEGATIVE SPIROCHETES</i>	133
<i>TABLE 68 GRAM-NEGATIVE OBLIGATE INTRACELLULAR PARASITES</i>	135
<i>TABLE 69 MISCELLANEOUS BACTERIA</i>	137
CHAPTER 10 APPENDIX B: LIST OF ACRONYMS	139

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL ANTIBIOTICS MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)	8
TABLE 1 DIFFERENCES BETWEEN GRAM-NEGATIVE AND GRAM-POSITIVE BACTERIA	11
TABLE 2 CLASSIFICATION OF BACTERIA BY SHAPE	13
TABLE 3 INCIDENCE OF COMMUNITY-ACQUIRED PNEUMONIA, 2010 (NO./%)	15
TABLE 4 INCIDENCE OF UPPER RESPIRATORY TRACT INFECTIONS CAUSED BY STREPTOCOCCUS, 2010 (NO./%)	15
TABLE 5 INCIDENCE OF URINARY TRACT INFECTIONS CAUSED BY STREPTOCOCCUS, 2010 (NO./%)	16
TABLE 6 INCIDENCE OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY STREPTOCOCCUS, 2010 (NO./%)	16
TABLE 7 PREVALENCE OF BACTERIAL VAGINOSIS INFECTIONS CAUSED BY STREPTOCOCCUS, 2010 (NO./%)	17
TABLE 8 TYPES OF ANTIBIOTICS AND METHODS OF RESISTANCE	18
TABLE 9 CURRENT AND EMERGING ANTIBIOTIC-RESISTANT BACTERIA	19
TABLE 10 U.S. LIFE EXPECTANCY AT BIRTH, 1920-2011 (YEARS)	23
TABLE 11 ANTIBIOTICS: YEAR OF INTRODUCTION, MODE OF ACTION AND TARGET SPECIES	23
TABLE 12 BIOCHEMICAL MECHANISM OF ANTIBIOTIC RESISTANCE	25
TABLE 13 ADDITIONAL COST AND LENGTH OF STAY DUE TO ANTIBIOTIC-RESISTANT BACTERIA IN THE U.S., ISRAEL AND SPAIN	26
TABLE 14 REASONS FOR LACK OF INNOVATION IN ANTIBIOTIC RESEARCH	45
TABLE 15 COMPARISON OF U.S. AND EU ORPHAN DRUG LEGISLATION AND PROCESS	59
TABLE 16 GLOBAL ANTIBIOTICS MARKET BY CLASS, THROUGH 2018 (\$ MILLIONS)	62
TABLE 17 GLOBAL ANTIBIOTICS MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)	62
TABLE 18 GLOBAL BETA-LACTAM ANTIBIOTICS MARKET BY TYPE, THROUGH 2018 (\$ MILLIONS)	63
TABLE 19 GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS BY REGION, THROUGH 2018 (\$ MILLIONS)	64
TABLE 20 GLOBAL PENICILLIN MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)	66
TABLE 21 TYPES OF PENICILLIN AND BRAND NAMES	67
TABLE 22 GLOBAL CEPHALOSPORIN MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)	68
TABLE 23 GENERATIONS OF CEPHALOSPORIN	69
TABLE 24 FIRST-GENERATION CEPHALOSPORINS	70
TABLE 25 SECOND-GENERATION CEPHALOSPORINS	71
TABLE 26 THIRD-GENERATION CEPHALOSPORINS	72
TABLE 27 FOURTH-GENERATION CEPHALOSPORINS	73
TABLE 28 FIFTH-GENERATION CEPHALOSPORINS	73
TABLE 29 GLOBAL CARBAPENEM MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)	74
TABLE 30 TYPES OF CARBAPENEMS	75
TABLE 31 GLOBAL MARKET FOR QUINOLONES BY GENERATION, THROUGH 2018 (\$ MILLIONS)	76
TABLE 32 GLOBAL MARKET FOR FLUOROQUINOLONES BY REGION, THROUGH 2018 (\$ MILLIONS)	77
TABLE 33 GLOBAL MARKET FOR SECOND-GENERATION FLUOROQUINOLONES BY REGION, THROUGH 2018 (\$ MILLIONS)	78
TABLE 34 GLOBAL MARKET FOR THIRD-GENERATION FLUOROQUINOLONES BY REGION, THROUGH 2018 (\$ MILLIONS)	79

TABLE HEADING	PAGE NO.
TABLE 35 GLOBAL MARKET FOR "OTHER" QUINOLONES BY REGION, THROUGH 2018 (\$ MILLIONS)	80
TABLE 36 TYPES OF QUINOLONES	80
TABLE 37 GLOBAL TETRACYCLINE MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)	82
TABLE 38 TYPES OF TETRACYCLINE	82
TABLE 39 GLOBAL MACROLIDE MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)	84
TABLE 40 TYPES OF MACROLIDES/KETOLIDES	84
TABLE 41 GLOBAL MARKET FOR "OTHER" ANTIBIOTICS BY REGION, THROUGH 2018 (\$ MILLIONS)	85
TABLE 42 DIFFERENCES BETWEEN ANTIBIOTIC USAGE IN ANIMALS AND HUMANS	87
TABLE 43 GLOBAL MARKET FOR VETERINARY ANTIBIOTICS BY APPLICATION, THROUGH 2018 (\$ MILLIONS)	88
TABLE 44 GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY TYPE, THROUGH 2018 (\$ MILLIONS)	90
TABLE 45 GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY ANIMAL TYPE, THROUGH 2018 (\$ MILLIONS)	90
TABLE 46 ASTRAZENECA REVENUES AND R&D EXPENDITURES, 2011-2013 (\$ MILLIONS)	94
TABLE 47 ASTRAZENECA DEVELOPMENTS	95
TABLE 48 BAYER REVENUES AND R & D EXPENDITURES, 2011-2013 (\$ MILLIONS)	96
TABLE 49 CUBIST PHARMACEUTICAL REVENUES AND R&D EXPENDITURES, 2011-2013	97
TABLE 50 CUBIST PHARMACEUTICAL DEVELOPMENTS	97
TABLE 51 GSK REVENUES AND R & D EXPENDITURES, 2011-2013 (\$ MILLIONS)	99
TABLE 52 GSK DEVELOPMENTS	99
TABLE 53 JOHNSON & JOHNSON REVENUES AND R&D EXPENDITURES, 2011-2013 (\$ MILLIONS)	100
TABLE 54 JOHNSON & JOHNSON DEVELOPMENTS	101
TABLE 55 MERCK & CO. REVENUES AND R&D EXPENDITURES, 2011-2013 (\$ MILLIONS)	102
TABLE 56 PFIZER REVENUES AND R&D EXPENDITURES, 2011-2013 (\$ MILLIONS)	103
TABLE 57 PFIZER DEVELOPMENTS	103
TABLE 58 LIST OF OTHER COMPANIES IN THE ANTIBIOTICS MARKET	104
TABLE 59 ANTIBIOTIC COMPOUNDS IN PHASE III CLINICAL TRIALS, 2013	111
TABLE 60 ANTIBIOTIC COMPOUNDS IN PHASE II CLINICAL TRIALS, 2013	112
TABLE 61 ANTIBIOTIC COMPOUNDS IN PHASE I CLINICAL TRIALS, 2013	113
TABLE 62 GRAM-POSITIVE BACTERIA	116
TABLE 63 GRAM-NEGATIVE BACTERIA	119
TABLE 64 GRAM-NEGATIVE COCCI	125
TABLE 65 GRAM-NEGATIVE RODS RELATED TO RESPIRATORY TRACT INFECTIONS	127
TABLE 66 GRAM-NEGATIVE RODS RELATED TO THE ENTERIC TRACT	128
TABLE 67 GRAM-NEGATIVE SPIROCHETES	133
TABLE 68 GRAM-NEGATIVE OBLIGATE INTRACELLULAR PARASITES	135
TABLE 69 MISCELLANEOUS BACTERIA	137

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL ANTIBIOTICS MARKET BY REGION, 2013-2018 (\$ MILLIONS)	8
FIGURE 1 CLASSIFICATION OF ANTIBIOTICS	21
FIGURE 2 CDC LIST OF MOST HIGHLY CONCERNING BACTERIA, PRIORITIZED ACCORDING TO THREAT LEVEL	26
FIGURE 3 INCREASE IN AGING POPULATION, 2011 AND 2050 (BILLIONS)	28
FIGURE 4 GLOBAL ANTIBIOTIC COMPANY MARKET SHARES, 2012 (%)	33
FIGURE 5 STRATEGIES TO PROMOTE ANTIBIOTIC RESEARCH	48
FIGURE 6 ANTIBIOTICS BY CLASS	62
FIGURE 7 TYPES OF BETA-LACTAM ANTIBIOTICS	65
FIGURE 8 ANTIBIOTICS IN PHASES I-III CLINICAL TRIALS, 2013 (%)	109
FIGURE 9 ANTIBIOTICS IN PHASE III CLINICAL TRIALS BY CLASS, 2013 (%)	110